Final answer:
If a pregnant woman with deep vein thrombosis (DVT) is on warfarin, a change to a low molecular weight heparin (LMWH) or unfractionated heparin is recommended due to the teratogenic effects of warfarin on the fetus.
Step-by-step explanation:
During pregnancy, the use of anticoagulation therapy must carefully consider both the well-being of the mother and the potential impact on the developing fetus. Warfarin, an oral anticoagulant, is associated with an increased risk of birth defects, particularly when used during the first trimester.
Therefore, in the case of a pregnant woman with DVT, the recommended change is to switch from warfarin to an alternative anticoagulant that is safer during pregnancy.
Low molecular weight heparins (LMWHs) and unfractionated heparin are often preferred alternatives in pregnancy because they do not cross the placenta as easily as warfarin, reducing the risk of teratogenic effects on the fetus. LMWHs, such as enoxaparin or dalteparin, are commonly used due to their favorable safety profile.
These anticoagulants have been found to be effective in preventing and treating thromboembolic events while minimizing the potential harm to the developing fetus. The decision to transition to a different anticoagulant should be made in consultation with a healthcare provider to ensure the best possible outcome for both the mother and the baby.
In summary, the change from warfarin to low molecular weight heparin or unfractionated heparin is a recommended adjustment for a pregnant woman with DVT. This switch is made to mitigate the teratogenic effects associated with warfarin, ensuring a safer anticoagulation strategy during pregnancy.